HEART TRANSPLANTATION. MARTIN SUSSMAN MILPARK HOSPITAL. ISSUES. Improvements in survival with medical therapy impacted on old indications for HT. Remain survival and QOL benefits for HF pts despite this Exercise testing strongly recommended, not routinely performed in JHB Peak VO2 < 12.
Biopsy 1, 2, 3, 4, and 5: Weekly
Biopsy 6, 7, and 8: Every 14 days
Biopsy 9 and 10: Every 3 weeks
Biopsy 11, 12, and 13: Every 4 weeks
Subsequent biopsies during
the 1st year after HT: Every 5 to 6 weeks
Generic Drug Immunosuppression in Thoracic Transplantation:An ISHLT Educational AdvisoryPatricia A. Uber, PharmD,a Heather J. Ross, MD,b Andreas O. Zuckermann, MD,c Stuart C. Sweet, MD,dPaul A. Corris, MD,e Keith McNeil, MD,f and Mandeep R. Mehra, MBBSa
1. Clinicians should educate their patients to inform
the coordinating center if a change in either the
labeling or appearance of their immunosuppressive
medications suggests that a generic drug substitution
2. Clinical care coordinating centers must develop
structured approaches for the education of all personnel
with regard to use of generic immunosuppressants.
3. In unique clinical situations, where critical drug
dosing represents a fine balance, caution should be
exercised in the use of generic immunosuppression.
4. Heightened vigilance to adverse sequelae and closer
therapeutic drug monitoring is indicated until a
stable immunosuppression milieu can be established